Cocrystal Pharma confirms $5 million OPKO Health private placement in 8-K filing

Cocrystal Pharma, Inc. filed an 8-K on August 3, 2026 detailing a $5 million private placement with OPKO Health, Inc. that closed on July 31, 2026. The company entered a Securities Purchase Agreement with OPKO, an accredited investor, and sold 5,474,053 shares of common stock at $0.9134 per share, which was the Nasdaq Consolidated Bid Price on the closing date, resulting in $5.0 million in gross proceeds.¹ The transaction did not include warrants or other derivative securities.¹

Dr. Phillip Frost, Chairman and CEO of OPKO, is also a co-founder, director and principal stockholder of Cocrystal.¹ Cocrystal said it plans to use the net proceeds, after offering expenses, to fund its preclinical and clinical drug programs as well as for general corporate purposes and working capital.¹

The share sale was exempt from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D, with OPKO qualifying as an accredited investor acquiring the shares for investment.¹

In the accompanying press release, CEO James Sapirstein said the company expects to report topline data from its Phase 1b norovirus trial by the end of the fourth quarter of 2026, and expressed gratitude for OPKO's continued conviction in the value of its lead asset, CDI-988, and its broader antiviral pipeline spanning influenza, coronaviruses and hepatitis C.¹ Separately, the filing's company description states CDI-988 is currently in a Phase 1b clinical trial for norovirus, with topline data expected in late 2026.¹

The 8-K was signed by Chief Financial Officer James Martin.¹